78 Results

People

  1. Seshan
    Seshan
  2. Younes
    Younes
  3. Zelenetz
    Zelenetz
  4. Batlevi
    Batlevi
  5. Matasar
    Matasar
  6. Palomba
    Palomba
  7. Horwitz
    Horwitz
  8. Noy
    Noy
  9. Dogan
    Dogan
  10. Kumar
    Kumar

Groups

  1. Biostatistics Service (78)
  2. Center for Hematologic Malignancies (78)
  3. Center for Pancreatic Cancer Research (78)
  4. Epidemiology and Biostatistics (78)
  5. Department of Medicine (72)
  6. Hematologic Malignancies, Division of (69)
  7. Lymphoma (63)
  8. Executive Committee, Center for Hematologic Malignancies (52)
  9. Sloan Kettering Institute Postdocs (46)
  10. Survivorship Research (38)
  1. "Center for Hematologic Malignancies"
  2. "Venkatraman Seshan"
Formats
  1. Meeting Abstract (40)
  2. Journal Article (35)
  3. Research Letter (3)
Groups
  1. Biostatistics Service (78)
  2. Center for Hematologic Malignancies (78)
  3. Center for Pancreatic Cancer Research (78)
  4. Epidemiology and Biostatistics (78)
  5. Department of Medicine (72)
  6. Hematologic Malignancies, Division of (69)

More Groups

People
  1. Venkatraman Seshan (78)
  2. Anas Younes (45)
  3. Andrew Zelenetz (41)
  4. Connie Batlevi (35)
  5. Ahmet Dogan (33)
  6. Maria Palomba (28)

More People

Years
  1. 2023 (9)
  2. 2022 (6)
  3. 2021 (11)
  4. 2020 (10)
  5. 2019 (8)
  6. 2018 (7)

More Years

Publications
  1. Blood (28)
  2. Hematological Oncology (7)
  3. Blood Cancer Journal (4)
  4. International Journal of Radiation Oncology, Biology, Physics (4)
  5. Blood Advances (3)
  6. JCI Insight (3)

More Publications

Publishers
  1. American Society of Hematology (31)
  2. Nature Publishing Group (9)
  3. Elsevier Inc. (8)
  4. Wiley Blackwell (8)
  5. American Association for Cancer Research (4)
  6. Amer Soc Clinical Investigation Inc (3)

More Publishers

Results (78)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of sequential CD19-directed therapies in relapsed and refractory large B cell lymphoma
    Meeting Abstract

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M. H.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G.; Romancik, J. T.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Genetic alterations of follicular lymphoma can predict response to very low dose radiotherapy
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E.; Chan, A.; Fregonese, B.; Seshan, V.; Hajj, C.; Cederquist, G.; Hubbeling, H.; Ma, J.; Sarkar, R. R.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Real-world outcomes in patients with transformed follicular lymphoma treated with CD19-targeting CAR-T therapy
    Meeting Abstract

    Rivas-Delgado, A.; Luttwak, E.; Drill, E.; Goldstein, I.; Landego, I.; Tomas, A. A.; Parascondola, A.; Saldia, A.; Caron, P.; Dahi, P. B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • A multicenter phase 2 trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in patients with treatment-naïve, TP53-mutant mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Soumerai, J.; Abramson, J. S.; Barnes, J. A.; Caron, P.; Chabowska, M.; Devlin, M.; Dogan, A.; Falchi, L.; Garcia, R. N.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study
    Research Letter

    Qualls, D. A.; Lambert, N.; Caimi, P. F.; Merrill, M.; Pullarkat, P.; Godby, R. C.; Bond, D. A.; Wehmeyer, G. T.; Romancik, J.; Amoozgar, B.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Journal Article

    Ptashkin, R. N.; Ewalt, M. D.; Jayakumaran, G.; Kiecka, I.; Bowman, A. S.; Yao, J. J.; Casanova, J.; Lin, Y. T. D.; Petrova-Drus, K.; Mohanty, A. S.; more...
    Nature Communications (2023)

    Fulltext@MSK | Save
  • The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry
    Research Letter

    Luttwak, E.; Noy, A.; Seshan, V.; Saltzman, L. A.; Greenberger, L. M.
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Long‐term follow-up of multicenter phase II trial of zanubrutinib, obinutuzumab, and venetoclax (BOVen) in previously untreated patients with CLL/SLL
    Meeting Abstract

    Soumerai, J. D.; Dogan, A.; Seshan, V.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Abramson, J. S.; Hamilton, A. M.; Noy, A.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Molecularly targeted epigenetic therapy with mocetinostat in relapsed and refractory non-Hodgkin lymphoma with CREBBP or EP300 mutations: An open label phase II study
    Research Letter

    Qualls, D.; Noy, A.; Straus, D.; Matasar, M.; Moskowitz, C.; Seshan, V.; Dogan, A.; Salles, G.; Younes, A.; Zelenetz, A. D.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save